Tactile Systems Technology, Inc.

Day range

$25.97 – $26.53

Open

$26.29

Prev close

$26.03

Volume

11.95K

Market cap

$583.11M

Shares out

22.34M

P/E

24.48

P/S

1.64

P/B

2.57

P/FCF

20.09

ROE

10.5%

ROA

8.2%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 6, 2026

• Quarterly earningsNov 2, 2026

  On November 2, 2026, Tactile Systems Technology, Inc. issued a press release disclosing its results of operations and financial condition for its most recently completed fiscal quarter.

• Product or service launchJul 13, 2026

  MyoSleeve expands our established market-leading portfolio by providing a new treatment option for appropriately selected patients in earlier stages of chronic swelling who may not yet require more intensive compression therapy. MyoSleeve has received U.S. Food and Drug Administration 510(k) clearance and is indicated for the treatment of chronic swelling, including chronic edema, lymphedema, and venous insufficiency.

• New auditor engagementMay 7, 2026

  The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Grant Thornton LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026

• Director appointmentMar 9, 2026

  On March 4, 2026, the board of directors of Tactile Systems Technology, Inc. (the "Company") elected Andrea A. Pearson to serve as a member of the board and fixed the size of the board at nine directors, all effective as of March 9, 2026. Ms. Pearson was also appointed to serve as a member of the Compliance and Reimbursement Committee and of the Nominating and Corporate Governance Committee of the board.

• Share repurchase programNov 3, 2025

  On November 3, 2025, we announced that our board of directors has authorized a new program to repurchase shares of our common stock in the open market or in privately negotiated purchases, or both, in an aggregate amount not to exceed $25 million. The share repurchase program became effective on November 3, 2025 and expires on November 3, 2027.

Days to cover

13.1

Short interest

2.83M

Avg volume

215.39K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Wall Street Analysts Think Tactile Systems Technology (TCMD) Could Surge 52.02%: Read This Before Placing a Bet
  positiveZacks Investment Research· Nov 4, 2026
• Tactile Systems: 3 Key Takeaways for Long-Term Investors
  positiveThe Motley Fool· Nov 3, 2026
• Tactile Systems Technology (TCMD) Q3 Earnings Surpass Estimates
  neutralZacks Investment Research· Nov 2, 2026
• Tactile Medical's Spending Outpaces Sales: Rapid Earnings Reaction
  negativeThe Motley Fool· Nov 2, 2026
• Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson
  positiveGlobeNewswire Inc.· Mar 9, 2026